Keyphrases
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
100%
Antihypertensive Treatment
100%
Urine Analysis
100%
Cost-utility
100%
Hypertensive Patients
60%
Resistant Hypertension
60%
Hypertension
40%
Quality-adjusted Life Years
40%
Treatment Adherence
40%
Further Analysis
20%
Intervention Strategies
20%
Cost Savings
20%
Systolic Blood Pressure
20%
Sensitivity Analysis
20%
Patient Samples
20%
Subgroup Analysis
20%
Health Benefits
20%
Care as Usual
20%
Blood Pressure Increase
20%
Cost-effective Strategy
20%
Markov Model
20%
Probabilistic Sensitivity Analysis
20%
Payer Perspective
20%
Healthcare Payer
20%
Young Patients
20%
Incremental Cost
20%
Cardiovascular Events
20%
Lifestyle Modification
20%
Antihypertensive Medication
20%
Non-adherence
20%
Patient Costs
20%
Risk for Cardiovascular Diseases
20%
High Systolic Blood Pressure
20%
Cost-utility Analysis
20%
Medicine and Dentistry
Health Care Cost
100%
Antihypertensive Therapy
100%
Liquid Chromatography-Mass Spectrometry
100%
Tandem Mass Spectrometry
100%
Urinalysis
100%
Drug Therapy
42%
Resistant Hypertension
42%
Systolic Blood Pressure
28%
Quality Adjusted Life Year
28%
Cardiovascular System
14%
Lifespan
14%
Cardiovascular Disease
14%
Base
14%
Lifestyle Modification
14%
Antihypertensive Agent
14%
Event Free Survival
14%
Subgroup Analysis
14%
Nursing and Health Professions
Liquid Chromatography-Mass Spectrometry
100%
Cost Utility Analysis
100%
Antihypertensive Therapy
100%
Urinalysis
100%
Drug Therapy
60%
Resistant Hypertension
60%
Cost Control
40%
Quality Adjusted Life Year
40%
Systolic Blood Pressure
40%
Cardiovascular Disease
20%
Lifestyle Modification
20%
Base
20%
Antihypertensive Agent
20%
Event Free Survival
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antihypertensive Agent
100%
Resistant Hypertension
100%
Pharmacotherapy
66%
Cardiovascular Disease
33%
Base
33%
Event Free Survival
33%